Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Net Margin (2020 - 2026)

Bioventus filings provide 5 years of Net Margin readings, the most recent being 10.97% for Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 10.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.8%, a N/A change, with the full-year FY2023 number at 14.53%, down 110.0% from a year prior.
  • Net Margin hit 10.97% in Q4 2025 for Bioventus, up from 2.89% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 29.99% in Q2 2021 to a low of 62.51% in Q2 2023.
  • Median Net Margin over the past 4 years was 0.34% (2022), compared with a mean of 6.22%.
  • Biggest five-year swings in Net Margin: skyrocketed 1666bps in 2021 and later crashed -6217bps in 2023.
  • Bioventus' Net Margin stood at 0.02% in 2021, then crashed by -96890bps to 18.59% in 2022, then plummeted by -236bps to 62.51% in 2023, then soared by 118bps to 10.97% in 2025.
  • The last three reported values for Net Margin were 10.97% (Q4 2025), 2.89% (Q3 2025), and 6.28% (Q2 2025) per Business Quant data.